Delving into the Latest Updates on TheraTarget, Inc. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Nervous System Diseases	3
Immune System Diseases	3
Endocrinology and Metabolic Disease	3
Hemic and Lymphatic Diseases	3
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Chemical drugs	2
Unknown	1

Top 5 Target	Count

PI3K family(Phosphatidylinositol 3-kinase family)	1
DNA x Top II	1
PDL1(Programmed death-ligand 1)	1
Ribonucleotide reductase	1
Tubulin	1

Cerebral aneurysms (CA), an abnormal bulge in the arteries that supply blood to the brain, are prone to rupture and can cause hemorrhagic stroke. Physicians can treat CA by blocking blood flow to the aneurysmal sac via clipping of the aneurysm neck via open procedure, or endovascular occlusion of the aneurysm with embolic materials to promote thrombus formation to prevent further inflow of blood into the aneurysm. Endovascular treatment options for CA still have significant limitations in terms of safety, usability in coagulopathic patients, and risks of device migration. Bioactive embolic therapies, consisting of non-toxic bioresorbable materials that encourage the growth of neointima across the aneurysm neck, are needed to improve the healing of CA. In this work, the bioinspired silk-elastinlike protein-based polymer (SELP 815K), was used to embolize aneurysms in a rabbit elastase model. SELP 815K effectively embolized the model aneurysms in vivo, achieving >90% occlusion, using commercial microcatheters. No device-associated adverse effects were observed in any of the animals, and SELP 815K showed no cytotoxicity. SELP embolization did not show any deleterious effects to local tissues, and features consistent with reendothelialization of the aneurysm neck were noted in histological examination one-month post-embolization. SELP 815K shows promise as an embolic treatment for unruptured CA. STATEMENT OF SIGNIFICANCE: Unruptured cerebral aneurysms are present in approximately 3% of the population, with a fatality rate of up to 65% upon rupture. In this work a silk-elastinlike protein polymer (SELP) is explored as a liquid embolic for occlusion of cerebral aneurysms. This embolic exists as a liquid at room temperature before rapidly forming a gel at physiological temperature. This shape filling property was used to successfully occlude cerebral aneurysms in rabbits, with stable occlusion persisting for over thirty days. SELP occlusions show evidence for reendothelialization of the aneurysm sac and provide an opportunity for delivery of bioactive agents to further improve treatments.

01 Dec 2014·Macromolecular BioscienceQ3 · ENGINEERING & TECHNOLOGY

In Vitro Synergistic Action of Geldanamycin- and Docetaxel-Containing HPMA Copolymer-RGDfK Conjugates Against Ovarian Cancer

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Cheney, Darwin L. ; Ray, Abhijit ; Buckway, Brandon ; Ghandehari, Hamidreza ; Larson, Nate ; Roberts, Sarah

HPMA copolymer-RGDfK (HPMA-RGDfK) conjugates bearing either aminohexylgeldanamycin (AHGDM) or docetaxel (DOC) were synthesized and characterized. In vitro stability and binding were evaluated. Cytotoxicity toward ovarian cancer cells was evaluated and the ability of the conjugates to induce cell death was assessed by combination index analysis. Conjugates bearing AHGDM were more stable and exhibited slower drug release than those bearing DOC. Both conjugates demonstrated the ability to bind to avb3 integrins. In combination, HPMA-RGDfK conjugates demonstrated marked synergism as compared to their non-targeted counterparts and free drug controls. HPMA-RGDfK conjugates bearing AHGDM and DOC induce synergistic cytotoxicity in vitro, suggesting their potential as a promising combination therapy.

100 Deals associated with TheraTarget, Inc.

Login to view more data

100 Translational Medicine associated with TheraTarget, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

7

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Epirubicin Hydrochloride ( DNA x Top II )	Solid tumor More	Phase 1
MPPA (TheraTarget) ( PDL1 )	Solid tumor More	Preclinical
Paclitaxel ( Tubulin )	Solid tumor More	Preclinical
Cyclopamine	Prostatic Cancer More	Preclinical
KT-8	-	Preclinical